CAMBRIDGE, Mass., Sept. 9, 2009 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced that clinical trial results from the Phase 2 EMINENCE trial of its rationally engineered anticoagulant, M118, will be presented at the 21st Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. The TCT conference is the world’s largest educational meeting specializing in interventional vascular medicine, with approximately 12,000 people expected to attend.
